05-28 Cumberland Pharmaceuticals Launches Vibativ Injection in China in Strategic Partnership with SciClone Pharmaceuticals Limited CI
04-29 SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
18/02/25 Cumberland Pharmaceuticals Inc. and SciClone Pharmaceuticals Limited Announce the National Medical Products Administration Approval of Cumberland's Vibativ® Injection in China CI
28/06/24 SciClone Pharmaceuticals Limited's Equity Buyback announced on June 6, 2023 has expired. CI
26/06/24 SciClone Pharmaceuticals Limited Announces Retirement of Wang Haixia as Non-Executive Director CI
21/06/24 SciClone Pharmaceuticals Limited(SEHK:6600) dropped from S&P Global BMI Index CI
16/05/24 Sciclone Pharmaceuticals Limited Announces Change of Address of Principal Place of Business in Hong Kong CI
18/04/24 Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31 MT
01/04/24 SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit MT
28/03/24 Sciclone Pharmaceuticals Limited Announces Executive Changes CI
28/03/24 Tranche Update on SciClone Pharmaceuticals Limited's Equity Buyback Plan announced on June 6, 2023. CI
28/03/24 SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
28/03/24 GL China Opportunities Fund IV L.P. and GL China Opportunities Fund IV L.P., managed by GL Capital Group and GL Capital Management GP L.P. agreed to acquire 66.69% stake in SciClone Pharmaceuticals Limited for HKD 7.9 billion. CI
Manager TitleAgeSince
Chief Executive Officer 61 01/06/2020
Director of Finance/CFO 47 28/04/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 01/06/2020
Chairman 62 01/06/2020
Director/Board Member 69 -
Date Insider Type Main position Quantity % Market Cap.
19/04/22Other

Chief Executive Officer

4,600,000 0.6712%
Change 5-day change 1-year change 3-year change Capi.($)
+0.86%+0.86% - - 1.47B
+0.76%+2.09%+20.88%-3.54% 67.96B
+0.08%-3.58%+44.96%+218.97% 54.4B
-2.10%+0.89%-49.30%-53.47% 41.74B
-2.79%+32.50%+32.50%+32.50% 40.63B
+3.74%-4.01%+133.49%-35.59% 30.38B
-0.72%-7.96%+49.53%-27.69% 29.37B
+1.07%+1.42%+72.47%+90.95% 23.68B
+3.88%+2.16%+11.78%+201.51% 19.15B
+15.12%+16.82%+96.11%+433.87% 17.68B
Average +0.35%+0.61%+45.82%+95.28% 36.11B
Weighted average by Cap. -0.00%-0.37%+37.78%+69.39%
Logo SciClone Pharmaceuticals (Holdings) Limited
SciClone Pharmaceuticals (Holdings) Ltd is a company principally engaged in the provision of treatment plans for tumors and severe infectious diseases. The Company and its subsidiaries are principally engaged in developing and commercializing a portfolio of marketed products as well as pipelines with potential in their focused therapeutic areas including oncology and severe infection. The Company’s main products comprise Zadaxin, Zometa, Oravig, Angiomax, Endoxan, Holoxan, Cytosafe, Farlutal, Campto and Vizimpro. The Company’s pipeline products include ORSERDU, Vaborem, Vibativ, RRx-001 and Omburtamab. The Company’s products are mainly used in fields such as tumors, urinary tract infections, and skin and soft tissue infections. The Company mainly conducts its businesses in the domestic market.
Employees
1,050
  1. Stock Market
  2. Stocks
  3. 6600 Stock